TABLE. Characteristics of patients with probable and confirmed mpox (N = 719) — New York City, May 19–July 15, 2022.
| Characteristic (no. with available information)* | No. (%) |
|---|---|
|
Age, yrs, median (IQR)
|
35 (31–41) |
|
Gender†
| |
| Female |
2 (0.3) |
| Male |
704 (97.9) |
| Transgender, nonbinary, or genderqueer |
12 (1.7) |
| Unknown |
1 (0.1) |
|
Sexual orientation
| |
| Bisexual |
40 (5.6) |
| Gay, lesbian, or queer |
566 (78.7) |
| Straight or heterosexual |
18 (2.5) |
| Unknown |
95 (13.2) |
|
Race and ethnicity
| |
| Asian or Pacific Islander |
37 (5.2) |
| Black or African American |
148 (20.6) |
| Hispanic or Latino |
212 (29.5) |
| White |
247 (34.4) |
| Unknown |
75 (10.4) |
|
Possible exposure ≤3 weeks before symptom onset
| |
|
Had intimate or sexual contact (n = 651)§
|
521 (80.0)
|
| No. of partners, median (IQR) |
3 (1–5) |
| Contact with men |
505 (77.6) |
| No. of partners, median (IQR) |
3 (1–5) |
| Contact with women |
17 (2.6) |
| No. of partners, median (IQR) |
1 (1–2) |
| Contact with persons who identify as transgender, nonbinary, genderqueer, or other gender identity |
7 (1.1) |
| No. of partners, median (IQR) |
1.5 (1–5) |
| Contact with persons with unknown gender identities |
6 (0.9) |
| No. of partners, median (IQR) |
1 (1–3) |
|
Self-reported contact with a person with suspected mpox (n = 611)¶,**
|
103 (16.9)
|
| Intimate or sexual contact |
66 (64.1) |
| Household contact |
5 (4.8) |
| Other |
13 (12.6) |
| Unknown |
20 (19.4) |
|
Symptomatic
| |
| Yes |
614 (85.4) |
| Unknown |
105 (14.6) |
|
Presence of prodrome (n = 614)
††
|
234 (38.1)
|
|
Sign or symptom (n = 614)
§§
| |
| Fever |
360 (58.6) |
| Body or muscle ache, myalgia, or back pain |
327 (53.3) |
| Fatigue |
319 (51.9) |
| Chills |
299 (48.7) |
| Lymphadenopathy |
298 (48.5) |
| Itching or pruritus |
291 (47.4) |
| Proctitis or rectal sign or symptom¶¶ |
277 (45.1) |
| Proctitis |
111 (40.0) |
| Constipation |
100 (36.1) |
| Tenesmus |
102 (36.8) |
| Rectal pain |
211 (76.2) |
| Rectal bleeding |
108 (39.0) |
| Blood in stool |
97 (35.0) |
| Headache |
253 (41.2) |
| Night sweats |
253 (41.2) |
| Malaise |
236 (38.4) |
| Sore throat |
173 (28.2) |
| Runny nose or cough |
118 (19.2) |
| Gastrointestinal*** |
96 (15.6) |
| Ophthalmic manifestations††† |
38 (6.2) |
|
Presence of skin lesion (n = 614)
| |
| Yes |
584 (95.1) |
| Unknown |
30 (4.9) |
|
No. of skin lesions (n = 584)
| |
| 1–9 |
227 (38.9) |
| 10–49 |
192 (32.8) |
| 50–99 |
20 (3.4) |
| ≥100 |
4 (0.7) |
| Unknown |
141 (24.1) |
|
Location of skin lesion (n = 584)§§§
| |
| Upper or lower extremities |
234 (40.1) |
| Genitals |
216 (37.0) |
| Face, mouth, or lip |
194 (33.2) |
| Torso (i.e., chest, abdomen, back, or trunk) |
184 (31.5) |
| Perianal |
117 (20.0) |
| Hand or foot |
116 (19.9) |
| Buttocks |
108 (18.5) |
| Scalp, head, or neck |
108 (18.4) |
| Palms or soles |
81 (13.9) |
| Eye |
3 (0.5) |
| Other |
85 (14.5) |
|
Location where skin lesion began (n = 584)
| |
| Genitals |
178 (30.5) |
| Upper or lower extremities |
134 (22.9) |
| Face, mouth, or lip |
98 (16.8) |
| Torso or back |
76 (13.0) |
| Perianal |
72 (12.3) |
| Palms or soles |
42 (7.2) |
| Neck |
28 (4.8) |
| Other |
87 (14.9) |
| Unknown |
143 (24.5) |
|
HIV infection, self- or provider-reported
|
181 (25.2) |
|
Interval from symptom onset to diagnosis, days, median (IQR)
|
5 (3–7) |
|
Receipt of PEP with JYNNEOS vaccine 0–14 days after last exposure
|
10 (1.4) |
|
Initiated treatment with tecovirimat
|
101 (14.0) |
| Hospitalized | 35 (4.9) |
Abbreviations: mpox = monkeypox; PEP = postexposure prophylaxis.
* Unknown category included patients with missing data or patients who responded “do not know” or “declined to answer” to the survey question.
† Transgender women or men are included with transgender, nonbinary, or genderqueer. Groups are mutually exclusive.
§ Patients could report intimate or sexual contact with more than one gender.
¶ Suspected mpox case defined as a person with a diagnosis of mpox or with compatible signs or symptoms. Patient could report more than one type of contact.
** Percentage of persons who reported contact with a person with suspected mpox.
†† Presence of nondermatologic signs or symptoms before onset of skin lesion.
§§ Patients could have more than one sign or symptom.
¶¶ Percentage of patients with proctitis or rectal signs or symptoms.
*** Includes nausea, vomiting, abdominal pain, or discomfort.
††† Includes eye lesion, conjunctivitis, red eyes, or eye discharge.
§§§ Patient could have skin lesions in more than one location.